Tracking Drug Development Cost Savings Through Risk-Based Monitoring
Drug development costs continue to rise and the life sciences industry is under greater pressure to increase efficiency and operating speed. The Drug Information Association (DIA) conference discussed costing strategies for sustainable drug development in a session chaired by Tufts Center for the Study of Drug Development's senior project manager Stella Stergiopoulos. Medidata's Kyle Given presented, "Tracking Cost Savings During Transformational Change: A Focus on Risk-Based Monitoring" and shares session highlights in this video recap.
*Guest blogger Kyle Given is a principal consultant at Medidata, supporting clients with risk-based monitoring programs.